Dr. Zhang on the ARCHES Trial in Prostate Cancer

Tian Zhang, MD
Published: Thursday, Nov 30, 2017



Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

The ARCHES trial is investigating enzalutamide (Xtandi) in the maintenance setting for patients with metastatic castration-sensitive disease.

It is enrolling patients with metastatic castration-sensitive prostate cancer and randomizes them to either enzalutamide or placebo. The standard of care for these patients was androgen deprivation therapy alone before the LATITUDE or CHAARTED data was published, explains Zhang.
 
SELECTED
LANGUAGE


Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

The ARCHES trial is investigating enzalutamide (Xtandi) in the maintenance setting for patients with metastatic castration-sensitive disease.

It is enrolling patients with metastatic castration-sensitive prostate cancer and randomizes them to either enzalutamide or placebo. The standard of care for these patients was androgen deprivation therapy alone before the LATITUDE or CHAARTED data was published, explains Zhang.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x